BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Merck
Chinese Patent Office
Medtronic
Express Scripts
Cipla
Deloitte
Mallinckrodt
Dow
Colorcon

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,544,799

« Back to Dashboard

Which drugs does patent 7,544,799 protect, and when does it expire?

Patent 7,544,799 protects GLEEVEC and is included in one NDA.

Protection for GLEEVEC has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 7,544,799
Title:Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Abstract:The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumour therapy. ##STR00001##
Inventor(s): Zimmermann; Jurg (Basel, CH), Sutter; Bertrand (Hesingue, FR), Burger; Hans M (Allschwil, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:11/515,997
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,544,799

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis GLEEVEC imatinib mesylate TABLET;ORAL 021588-001 Apr 18, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Novartis GLEEVEC imatinib mesylate TABLET;ORAL 021588-002 Apr 18, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,544,799

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1764/97Jul 18, 1997

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Harvard Business School
Fuji
Colorcon
Queensland Health
Deloitte
Baxter
Mallinckrodt
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot